Left ventricular hypertrophy and angiotensin II antagonists

American Journal of Hypertension

Volumn 14, Issue 2, 2001, Pages 174-182

  Dahlöf, Bjorn ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin II antagonists; Left ventricular hypertrophy; Losartan; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HORMONE ANTAGONISTS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 0035112870     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(00)01257-7     Document Type: Review

References (69)

1. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study
2. Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham Heart Study
3. Echocardiographic dimensions in borderline and sustained hypertension
4. Left ventricular hypertrophy and mortality in hypertension: An analysis of data from the Glasgow Blood Pressure Clinic
5. Assessment of left-ventricular mass and its response to antihypertensive treatment
6. Regression of increased left ventricular mass by antihypertensives
7. Reversal of left ventricular hypertrophy in hypertensive patients. Metaanalysis of 109 treatment studies
8. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies
9. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents
10. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system
11. Structural cardiovascular changes in essential hypertension. Studies on the effects of antihypertensive therapy
12. Regression of cardiovascular structural changes - A preventative strategy
13. Prognostic significance of regression of left ventricular hypertrophy
14. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system
15. Factors associated with reactive and reparative fibrosis of the myocardium
16. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality
17. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue in angiotensin II in spontaneously hypertensive rats
18. Angiotensin and cell growth: A link to cardiovascular hypertrophy?
19. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression
20. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension?
21. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension
22. Inadequate suppression of angiotensin II modulates left ventricular structure in humans
23. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats
24. Changes in collagen phenotypes during progression and regression of cardiac hypertrophy
25. Nonpeptide angiotensin II receptor antagonists
26. Angiotensin II receptors and angiotensin II receptor antagonists
27. Receptors and their classification: Focus and angiotensin II and the AT2 receptor
28. 2 receptor: Searching for signal-transduction pathways and physiological function
29. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells
30. The angiotensin II type 2 (AT2) receptor antagonized the growth effects of the AT1 receptor: Gain-of-function study using gene transfer
31. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects
32. Angiotensin II receptor expression in the infarcted human heart
33. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart
34. A chymase-angiotensin system in humans
35. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension
36. Losartan regresses left ventricular hypertrophy and improves ejection fraction in hypertensive diabetic patients
37. Effects of chronic treatment with the angiotensin II antagonist losartan on left ventricular anatomy and function and microalbuminuria in hypertensives
38. The effect of angiotensin II antagonism on ventricular hypertrophy
39. Effects of losartan on left ventricular mass and heart rate variability in hypertensive patients
40. The effects of angiotensin II receptor antagonist (AT II A) on urinary albumin excretion (UAE), left ventricular mass (LVM), diastolic and systolic function and lipid profile in essential hypertension (EH)
41. A new therapeutic approach to left ventricular hypertrophy
42. 1-receptor blockade in human hypertension
43. Losartan attenuates norepinephrine levels, regresses left ventricular hypertrophy and improves ejection fraction in post-infarction hypertensive diabetic patients
44. Effect of losartan on diastolic function in hypertensive patients with left ventricular hypertrophy
45. The effects of the angiotensin II antagonists on blood pressure and ventricular mass
46. Effects of an angiotensin II receptor antagonist on urinary albumin excretion, left ventricular mass, and systolic and diastolic blood pressures in essential hypertension
47. The effect of antihypertensive treatment with an antagonist of angiotensin II on the structural characteristics of the left ventricle
48. Increased left-ventricular mass after losartan treatment
49. Tackling ACE-inhibitor cough
50. Regression of left ventricular hypertrophy and effects on renal function during antihypertensive treatment with losartan in a two-year follow-up
51. The effects of antihypertensive therapy with losartan on left ventricular mass in 3-year follow up in the elderly
52. Losartan in essential hypertension: Effects on blood pressure and left ventricular mass
53. Effects of losartan on blood pressure and left ventricular mass in essential hypertension
54. Antihypertensive therapy with losartan and fosinopril: Efficacy in left ventricular hypertrophy regression
55. The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension
56. Effects of losartan on hypertension and left ventricular mass: A long-term study
57. Effects of losartan titrated to losartan/hydrochlorthiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study
58. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
59. Correlation of left ventricular hypertrophy and pulse pressure after 48 weeks of therapy with irbesartan and atenolol
60. Comparison of irbesartan vs felodipine after 1 year in the regression of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression
61. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension
62. Meta-analyses of randomized controlled trials
63. Criteria for an informative trial of left ventricular hypertrophy regression
64. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials
65. Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis
66. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy
67. Prognostic implications of baseline electrocardiographic features and their serial changes in patients with left ventricular hypertrophy
68. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
69. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Rationale, design, and methods